Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics’ chief commercial officer Peter Heerma reported a mix of equity award vesting and a required tax-related sale. On May 4, 2026, 4,250 performance-based restricted stock units (PSUs) vested, converting into 4,250 shares of common stock after Travere confirmed a FILSPARI cumulative net revenue performance milestone tied to results for the quarter ended March 31, 2026.
Those PSUs are part of an 8,500-unit grant awarded on January 31, 2024, with an additional 25% scheduled to vest on January 31, 2027, contingent on continued service. The filing notes that up to 50% additional shares could vest later if certain milestones are achieved on an accelerated timeline. On May 5, 2026, Heerma sold 2,174 shares at $46.65 per share to cover tax withholding obligations under a mandatory “sell to cover” arrangement chosen by the company, described as a non-discretionary sale. After these transactions, he directly holds 140,684 shares of Travere common stock.
Travere Therapeutics CEO Eric M. Dube exercised performance-based restricted stock units and sold shares in a planned, routine transaction. On May 6, 2026, he sold 22,500 shares of common stock at $43.95 per share in an open-market trade under a pre-arranged Rule 10b5-1(c) plan that also covered tax obligations from vesting.
Two days earlier, on May 4, 2026, he exercised 22,500 performance-based restricted stock units into common shares and received a new grant covering 45,000 PSUs. The filing states 50% of these PSUs vested after a cumulative FILSPARI net revenue performance target was confirmed, with an additional 25% scheduled to vest on January 31, 2027 if he remains in continuous service.
After these transactions, Dube directly holds 432,886 shares of Travere Therapeutics common stock, indicating he retains a substantial equity stake.
Travere Therapeutics’ CFO Christopher R. Cline reported a mix of equity awards, vesting and share sales. On May 4, 2026, he exercised performance-based restricted stock units (PSUs) covering 4,250 shares of common stock at a conversion price of $0.00 per share, following the vesting of 50% of PSUs originally granted on January 31, 2024. Those PSUs vested after the company confirmed that a performance criterion tied to cumulative FILSPARI net revenue for the quarter ended March 31, 2026 had been achieved. The same grant allows up to 50% additional shares to vest on an accelerated timeline and provides that a further 25% will vest on January 31, 2027, contingent on continued service.
Also on May 4, 2026, he received a new grant of 8,500 PSUs, each representing a contingent right to one share of common stock at target, subject to performance adjustments. On May 5 and May 6, 2026, he sold a total of 2,491 shares of common stock at prices of $46.65 and $43.95 per share. According to the footnotes, these sales were executed under a written Rule 10b5-1(c) trading plan adopted on May 28, 2025 and include shares sold to cover tax withholding obligations arising from PSU vesting. After these transactions, he directly owned 118,658 shares of Travere Therapeutics common stock.
Christopher Cline submitted a Form 144 notice to sell common stock classified as Performance Shares as an issuer transaction. The filing lists multiple recent dispositions by Cline: 2,181 shares on 05/05/2026 ($101,743.65), 1,014 shares on 04/15/2026 ($43,206.54), 7,239 shares on 04/14/2026 ($303,522.58), plus smaller trades on 04/14/2026 (9 shares, $369.63) and 04/13/2026 (65 shares, $1,875.25).
Elizabeth Reed filed a Form 144 reporting an intended sale of 2,076 shares of Common Stock (listed as Performance Shares) with an execution date of 05/04/2026.
The filing lists prior sales by the same holder during the past three months, including a 20,000-share sale on 05/04/2026 and a 37,500-share sale on 04/14/2026, with corresponding proceeds shown in the excerpt.
Insider sales reported on Form 144 for TVTX. The filing lists multiple dispositions of common stock by Jula Inrig and related entries: 20,000 shares sold on 05/04/2026 for $900,000, 7,215 shares on 04/14/2026 for $302,516.29, 1,018 shares on 04/15/2026 for $43,376.98, and 2,174 shares on 05/05/2026 for $101,417.10. The securities type is listed as Performance Shares and the trades are identified as issuer transactions.
TVTX insider sale notice filed on Form 144. The filing reports 22,500 shares of Common Stock associated with a restricted stock vesting event dated 05/04/2026, with Fidelity Brokerage Services LLC listed as broker.
The filing also discloses recent dispositions by Eric M. Dube: 60,000 shares on 02/20/2026 for $1,805,765.69, 60,000 shares on 04/01/2026 for $1,855,654.74, and 64,000 shares on 04/15/2026 for $2,629,832.99.
TVTX reported a Form 144 notice showing a sale of 9,100 shares by William E. Rote on 04/22/2026 for $355,719.00. The filing also lists 2,763 restricted shares scheduled for vesting on 05/04/2026 as compensation.
Reporting person filed a Form 144 reporting the proposed sale of 2,181 shares of common stock on 05/04/2026 following the vesting of Performance Restricted Stock Units. The filing also lists recent open-market dispositions by Christopher Cline: 1,014 shares for $43,206.54, 7,239 shares for $303,522.58, 9 shares for $369.63, and 65 shares for $1,875.25.
TVTX filed a Form 144 reporting planned and recent sales of Common Stock by an insider/affiliate. The filing lists 2,174 shares tied to a Performance Restricted Stock Unit vesting on 05/04/2026 and multiple disposition entries by Elizabeth E. Reed between 02/17/2026 and 05/04/2026, including a sale of 20,000 shares for $900,000 on 05/04/2026.